Detalle Publicación

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Autores: Krop, Ian E.; Kim, Sung-Bae; González Martín, Antonio; LoRusso, Patricia M.; Ferrero, Jean-Marc; Smitt, Melanie; Yu, Ron; Leung, Abraham C. F.; Wildiers, Hans; TH3RESA Study Collaborators
Título de la revista: LANCET ONCOLOGY
ISSN: 1474-5488
Volumen: 15
Número: 7
Páginas: 689-699
Fecha de publicación: 2014
Resumen:
Trastuzumab emtansine should be considered as a new standard for patients with HER2-positive advanced breast cancer who have previously received trastuzumab and lapatinib.
DOI: https://doi.org/10.1016/S1470-2045(14)70178-0
Impacto:
578 citas en
Google Scholar